Other Trials

Research and Education > TriHealth Hatton Research Institute

In addition to trials sponsored by the medical industry, TriHealth hospitals participate in clinical research supported by grants from government organizations and private foundations. Such research is diverse; at any given time, research teams are conducting studies in several specialty areas: cardiology, cardiothoracic and vascular surgery, dermatology, neonatology, neurosurgery, obstetrics and gynecology, oncology, orthopedics, urogynecology, and would healing.

More than 20 grant-supported trials currently are being conducted. A selection of these trials is listed below; for more information or to participate, please call the appropriate contact person.


Other Clinical Trials

Other

 

Growth Regulation in Fetuses with Cardiac Malformations

Pl: Andrea Hinton MD
Contact Person: Ganga Devaiah MS, 513 862 2341 or Ganga_devaiah@trihealth.com; or Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com

Inclusion Criteria:  

  • Fetal diagnosis of Hypoplastic Left Heart Syndrome
  • Clinically obtained amniocentesis

Exclusion Criteria:

  • Genetic syndrome diagnosis (e.g. Turner Syndrome)
  • Mother with a condition that potentially results in growth abnormalities (e.g. preeclampsia, diabetes, abnormal quad screen).
  • Advanced maternal age >35 years
  • Mothers less than 18 years of age
 

Randomized Multi-Center of Antenatal Treatment of Alloimmune Thrombocytopenia

PI: William Polzin MD
Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com

Inclusion Criteria: Very High Risk Group

  • Pregnant women are eligible for inclusion into the very high risk group if they:
    • Are PLA-1 negative and have known platelet incompatibility with their fetus
    • Have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation
    • Are less than study 19 weeks gestation
     

Exclusion Criteria: Very High Risk Group

  • Women are not eligible for inclusion into the very high risk group if they:
    • Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
    • Are greater than 19 weeks gestation
     

Inclusion Criteria: High Risk Group

  • Pregnant women are eligible for inclusion into the high risk group if they:
    • Are PLA-1 negative and have known platelet incompatibility with the fetus
    • Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
    • Are between 12-30 weeks of gestation
     

Exclusion Criteria: High Risk Group

  • Women are not eligible for inclusion into the high risk group if they:
    • Have had a previous child who suffered an antenatal hemorrhage prior 28 weeks gestation
    • Are greater than 30 weeks gestation
     

Inclusion Criteria: Standard Risk Group

  • Pregnant women are eligible for inclusion into the standard risk group if they:
    • Are PLA_1 negative and have known platelet incompatibility with the fetus
    • Have not had a previous child who suffered an antenatal hemorrhage
    • Are between 20-30 weeks of gestation
    ;

Exclusion Criteria: Standard Risk Group

  • Women are not eligible for inclusion into the standard risk group if they:
    • Have had a previous child who suffered an antenatal hemorrhage
    • Are greater than 30 weeks gestation 
     
 

Novel Biomarkers in Amniotic Fluid to Predict Fetal Lung Maturity and Clinical Respiratory Outcomes

PI: Beena Kamath MD
Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com
Inclusion Criteria:

  • 18 years of age or older
  • Pregnant between 34 to < 39 weeks gestation
  • Amniocenteses
 

A Phase III, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of LIBIGEL for the Treatment of Hypoactive Sexual Desire (HSDD) in Postmenopausal Women

PI: Rachel Pauls MD
Contact Person: Vivian Ghodsi RN CCRC, 513 463 4308 or Vivian_Ghodsi@TriHealth.com

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Closure of Pfannenstiel Skin Incisions after Cesarean Delivery:  A comparison of Metallic Staples versus Absorbable Staples

PI: Catherine Feese MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or  Michaela_Eschenbacher@TriHealth.com 

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance

PI: Donna Lambers MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Assessment of Pain and Embarrassment with Urodynamic Testing in Women: A Prospective Study

PI: Rachel Pauls MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com      

  • Inclusion Criteria: Closed to enrollment. Follow-up only
  • Exclusion Criteria: Closed to enrollment. Follow-up only
 

Mechanisms of Correction of Fetal Growth Restriction

PI: Mounira Habli MD
Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com

  • Inclusion: All healthy pregnant females between 19-45 scheduled for a csection at >37 weeks between Monday and Friday
  • Exclusion: All preterm scheduled csections, medically complicated patients, and patients who refuse participation
 

We are physicians, hospitals and communities working together to help you live better.